Investigators have identified a potential biomarker for response to proteasome inhibitors in patients with multiple myeloma. The research also provides intriguing clues about possible new therapeutic ...
A phase II trial of high-dose radiotherapy (60 Gy) and UFT/l-leucovorin in patients with locally advanced rectal cancer (LARC): Long-term results This is an ASCO Meeting Abstract from the 2004 ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results